ATC code none PubChem CID 10275777 UNII 74RWP7W0J9 | CAS Number 330942-05-7 ChemSpider 18981107 Molar mass 451.905 g/mol | |
 | ||
Legal status Being evaluated in the global Phase 3 trial (APEX) | ||
Betrixaban (INN, codenamed PRT-054,021) is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is potent, orally active and highly selective for factor Xa, being selected from a group of similar compounds for its low hERG affinity. Betrixaban has undergone human clinical trials for prevention of embolism after knee surgery, and prevention of stroke following atrial fibrillation, with promising results. Betrixaban is currently being studied in a human clinical trial for extended duration thromboprophylaxis to prevent venous thromboembolism in acute medically ill patients. Joint development with Portola was discontinued in 2011 by Merck. Betrixaban is now being developed by Portola Pharmaceuticals.
References
Betrixaban Wikipedia(Text) CC BY-SA